A/S Novo Nordisk (preparation, filling in primary packaging, lyophilization and testing of finished medicinal product, quality control (microbiological testing) of finished medicinal product; quality control of finished medicinal product; labeling and secondary packaging of finished medicinal product, addition of scale to injection syringe); responsible for batch release of finished medicinal product
UkraineAll drugs from this manufacturer
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder for injection solution
Active substance Dosage turoctocog alfa 250 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder for injection solution
Active substance Dosage turoctocog alfa 500 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder for injection solution
Active substance Dosage turoctocog alfa 1000 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (a disease caused by a deficiency of factor VIII).
Dosage form: powder for injection solution
Active substance Dosage turoctocog alfa 3000 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder for injection solution
Active substance Dosage turoctocog alfa 1500 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder for injection solution
Active substance Dosage turoctocog alfa 2000 IU ATC: B02BD02